Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3
Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3
复制标题
DOI：
10.3109/09286586.2013.766757
复制
发表时间：
2013-04-01
影响因子：
1.8
通讯作者：
Vingerling, Johannes R.
中科院分区：
文献类型：
--
作者：
Clemons, Traci E.;Gillies, Mark C.;Vingerling, Johannes R.
目的：确定Mactel项目自然历史观察(NHO)研究参与者中各种系统性疾病的患病率是否与普通人群中相应的患病率不同。方法：本报告将NHO研究参与者的系统性疾病患病率与来自美国、荷兰和澳大利亚的三项基于人群的研究中年龄和性别匹配的对照进行比较。Bootstrap模拟被用来评估计算统计的影响和可靠性。结果：我们发现了一些在黄斑毛细血管扩张(Mactel)2型患者中似乎比普通人群中更常见的系统性疾病，这些患者的年龄和性别与Mactel患者的年龄和性别相匹配。在一般老年社区中，与同龄同龄人相比，2型Mactel患者的糖尿病患病率、肥胖率、高血压和心血管病史显著增加。结论：与Mactel 2型相关的系统性疾病可能有助于提高对Mactel 2型的可能原因的了解。希望未来的研究将有助于提高我们对这种疾病的发病机制的理解，并为这种眼病提供潜在的治疗方法。
Purpose: To determine whether the prevalences of various systemic conditions in participants of the MacTel Project Natural History Observation (NHO) Study differ from the corresponding prevalences in the general population.Methods: This report compares the prevalence of systemic disease in participants of the NHO Study with age- and sex-matched controls from three population-based studies from the US, the Netherlands and Australia. Bootstrap simulations were used to evaluate the impact and reliability of the computed statistics.Results: We identified a number of systemic conditions that appear to be more prevalent in cases with macular telangiectasia (MacTel) Type 2 than in the general population that were matched for age and sex with the MacTel cases. Patients with MacTel Type 2 had significantly increased prevalence of diabetes mellitus, higher prevalence of obesity, hypertension and history of cardiovascular disease, compared to their same-aged peers in generally older communities.Conclusion: Systemic disease associated with MacTel Type 2 may help to improve understanding of possible causes of MacTel Type 2. It is hoped that future studies will help to improve our understanding of the pathogenesis of the condition and lead to potential treatments for this ocular disease.